Cyclooxygenase products and atherosclerosis

MacRae F. Linton, Sergio Fazio

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Prostaglandins (PGs) and their specific receptors play critical roles in atherothrombosis. Produced from arachidonic acid via two cyclooxygenase (COX) isoforms, PGs mediate their actions via G-protein coupled receptors. Thromboxane (TX) A2 is a vasoconstrictor and platelet agonist, prostacyclin (PGI2) is a vasodilator that inhibits platelet function, and PGE2 modulates inflammation. The cardioprotective effects of aspirin are attributed to inhibition of COX-1 mediated platelet TX production. In contrast, the selective COX-2 inhibitor, rofecoxib, was removed from the market due increased cardiovascular events. Studies of pharmacological modulation of PGs and genetic deletion of specific PG receptors in murine models have provided insights into their roles in atherosclerosis, but murine models have major limitations in addressing issues of plaque rupture and thrombosis. Nonselective COX inhibition, COX-1 inhibition, TP antagonism, and deletion of the TX receptor (TP) reduce atherosclerosis in murine models; yet, elimination of COX-1 or TP expression in bone marrow-derived cells does not reduce atherosclerosis, indicating that COX-1-mediated platelet TX production is not a major driving force in murine atherogenesis. The results of COX-2 inhibition on atherosclerosis have been mixed with studies showing increased, decreased or unchanged lesion area, suggesting that the impact of COX-2 inhibition may vary with lesion stage. However, COX-2 inhibition or COX-2 gene deletion have a profound ability to prevent angiotensin II-induced aneurysm formation in mice. A number of studies have shown that genetic deletion of the PGI2 receptor (IP) accelerates the vascular response to injury. However, the data do not support a "balance" between COX-2-derived PGI2 and COX-1-derived platelet TX as a critical determinant of atherogenesis. Genetic deletion of microsomal PGES-1, a synthase that produces PGE2, reduces atherosclerosis, an effect attributed to increased PGI2 production. PGE2 modulates inflammation and may impact atherogenesis directly via a number of mechanisms. A more detailed understanding of the roles of PGs and their receptors in atherothrombosis may point to more specific targets for the prevention of atherosclerotic cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)25-36
Number of pages12
JournalDrug Discovery Today: Therapeutic Strategies
Volume5
Issue number1
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Prostaglandin-Endoperoxide Synthases
Atherosclerosis
Cyclooxygenase 1
Cyclooxygenase 2
Epoprostenol
Blood Platelets
Thromboxanes
Prostaglandin Receptors
Dinoprostone
Prostaglandins
Epoprostenol Receptors
Thromboxane Receptors
Inflammation
Thromboxane A2
Cyclooxygenase 2 Inhibitors
Gene Deletion
Vasoconstrictor Agents
G-Protein-Coupled Receptors
Vasodilator Agents
Arachidonic Acid

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Cyclooxygenase products and atherosclerosis. / Linton, MacRae F.; Fazio, Sergio.

In: Drug Discovery Today: Therapeutic Strategies, Vol. 5, No. 1, 03.2008, p. 25-36.

Research output: Contribution to journalArticle

@article{99c5a5e52d94435aa5f9fd1e3caa6bcd,
title = "Cyclooxygenase products and atherosclerosis",
abstract = "Prostaglandins (PGs) and their specific receptors play critical roles in atherothrombosis. Produced from arachidonic acid via two cyclooxygenase (COX) isoforms, PGs mediate their actions via G-protein coupled receptors. Thromboxane (TX) A2 is a vasoconstrictor and platelet agonist, prostacyclin (PGI2) is a vasodilator that inhibits platelet function, and PGE2 modulates inflammation. The cardioprotective effects of aspirin are attributed to inhibition of COX-1 mediated platelet TX production. In contrast, the selective COX-2 inhibitor, rofecoxib, was removed from the market due increased cardiovascular events. Studies of pharmacological modulation of PGs and genetic deletion of specific PG receptors in murine models have provided insights into their roles in atherosclerosis, but murine models have major limitations in addressing issues of plaque rupture and thrombosis. Nonselective COX inhibition, COX-1 inhibition, TP antagonism, and deletion of the TX receptor (TP) reduce atherosclerosis in murine models; yet, elimination of COX-1 or TP expression in bone marrow-derived cells does not reduce atherosclerosis, indicating that COX-1-mediated platelet TX production is not a major driving force in murine atherogenesis. The results of COX-2 inhibition on atherosclerosis have been mixed with studies showing increased, decreased or unchanged lesion area, suggesting that the impact of COX-2 inhibition may vary with lesion stage. However, COX-2 inhibition or COX-2 gene deletion have a profound ability to prevent angiotensin II-induced aneurysm formation in mice. A number of studies have shown that genetic deletion of the PGI2 receptor (IP) accelerates the vascular response to injury. However, the data do not support a {"}balance{"} between COX-2-derived PGI2 and COX-1-derived platelet TX as a critical determinant of atherogenesis. Genetic deletion of microsomal PGES-1, a synthase that produces PGE2, reduces atherosclerosis, an effect attributed to increased PGI2 production. PGE2 modulates inflammation and may impact atherogenesis directly via a number of mechanisms. A more detailed understanding of the roles of PGs and their receptors in atherothrombosis may point to more specific targets for the prevention of atherosclerotic cardiovascular disease.",
author = "Linton, {MacRae F.} and Sergio Fazio",
year = "2008",
month = "3",
doi = "10.1016/j.ddstr.2008.05.006",
language = "English (US)",
volume = "5",
pages = "25--36",
journal = "Drug Discovery Today: Therapeutic Strategies",
issn = "1740-6773",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Cyclooxygenase products and atherosclerosis

AU - Linton, MacRae F.

AU - Fazio, Sergio

PY - 2008/3

Y1 - 2008/3

N2 - Prostaglandins (PGs) and their specific receptors play critical roles in atherothrombosis. Produced from arachidonic acid via two cyclooxygenase (COX) isoforms, PGs mediate their actions via G-protein coupled receptors. Thromboxane (TX) A2 is a vasoconstrictor and platelet agonist, prostacyclin (PGI2) is a vasodilator that inhibits platelet function, and PGE2 modulates inflammation. The cardioprotective effects of aspirin are attributed to inhibition of COX-1 mediated platelet TX production. In contrast, the selective COX-2 inhibitor, rofecoxib, was removed from the market due increased cardiovascular events. Studies of pharmacological modulation of PGs and genetic deletion of specific PG receptors in murine models have provided insights into their roles in atherosclerosis, but murine models have major limitations in addressing issues of plaque rupture and thrombosis. Nonselective COX inhibition, COX-1 inhibition, TP antagonism, and deletion of the TX receptor (TP) reduce atherosclerosis in murine models; yet, elimination of COX-1 or TP expression in bone marrow-derived cells does not reduce atherosclerosis, indicating that COX-1-mediated platelet TX production is not a major driving force in murine atherogenesis. The results of COX-2 inhibition on atherosclerosis have been mixed with studies showing increased, decreased or unchanged lesion area, suggesting that the impact of COX-2 inhibition may vary with lesion stage. However, COX-2 inhibition or COX-2 gene deletion have a profound ability to prevent angiotensin II-induced aneurysm formation in mice. A number of studies have shown that genetic deletion of the PGI2 receptor (IP) accelerates the vascular response to injury. However, the data do not support a "balance" between COX-2-derived PGI2 and COX-1-derived platelet TX as a critical determinant of atherogenesis. Genetic deletion of microsomal PGES-1, a synthase that produces PGE2, reduces atherosclerosis, an effect attributed to increased PGI2 production. PGE2 modulates inflammation and may impact atherogenesis directly via a number of mechanisms. A more detailed understanding of the roles of PGs and their receptors in atherothrombosis may point to more specific targets for the prevention of atherosclerotic cardiovascular disease.

AB - Prostaglandins (PGs) and their specific receptors play critical roles in atherothrombosis. Produced from arachidonic acid via two cyclooxygenase (COX) isoforms, PGs mediate their actions via G-protein coupled receptors. Thromboxane (TX) A2 is a vasoconstrictor and platelet agonist, prostacyclin (PGI2) is a vasodilator that inhibits platelet function, and PGE2 modulates inflammation. The cardioprotective effects of aspirin are attributed to inhibition of COX-1 mediated platelet TX production. In contrast, the selective COX-2 inhibitor, rofecoxib, was removed from the market due increased cardiovascular events. Studies of pharmacological modulation of PGs and genetic deletion of specific PG receptors in murine models have provided insights into their roles in atherosclerosis, but murine models have major limitations in addressing issues of plaque rupture and thrombosis. Nonselective COX inhibition, COX-1 inhibition, TP antagonism, and deletion of the TX receptor (TP) reduce atherosclerosis in murine models; yet, elimination of COX-1 or TP expression in bone marrow-derived cells does not reduce atherosclerosis, indicating that COX-1-mediated platelet TX production is not a major driving force in murine atherogenesis. The results of COX-2 inhibition on atherosclerosis have been mixed with studies showing increased, decreased or unchanged lesion area, suggesting that the impact of COX-2 inhibition may vary with lesion stage. However, COX-2 inhibition or COX-2 gene deletion have a profound ability to prevent angiotensin II-induced aneurysm formation in mice. A number of studies have shown that genetic deletion of the PGI2 receptor (IP) accelerates the vascular response to injury. However, the data do not support a "balance" between COX-2-derived PGI2 and COX-1-derived platelet TX as a critical determinant of atherogenesis. Genetic deletion of microsomal PGES-1, a synthase that produces PGE2, reduces atherosclerosis, an effect attributed to increased PGI2 production. PGE2 modulates inflammation and may impact atherogenesis directly via a number of mechanisms. A more detailed understanding of the roles of PGs and their receptors in atherothrombosis may point to more specific targets for the prevention of atherosclerotic cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=56449086128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449086128&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2008.05.006

DO - 10.1016/j.ddstr.2008.05.006

M3 - Article

AN - SCOPUS:56449086128

VL - 5

SP - 25

EP - 36

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

SN - 1740-6773

IS - 1

ER -